David Borg
Impact in
- Oncology top 1%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
-
- Gastric Cancer Management and Outcomes
Papers in
- Oncology 17
- Cancer Immunotherapy and Biomarkers 7
- Pancreatic and Hepatic Oncology Research 4
- HER2/EGFR in Cancer Research 4
- Cancer Cells and Metastasis 1
- Colorectal Cancer Treatments and Studies 1
-
- Gastric Cancer Management and Outcomes 10
- Co-authors
- Karin Jirström (15 shared papers)Björn Nodin (13 shared papers)Charlotta Hedner (15 shared papers)Bobby Tingstedt (1 shared paper)Daniel Ansari (1 shared paper)Caroline Williamsson (1 shared paper)Monika Posaric Bauden (1 shared paper)Agata Sasor (1 shared paper)
- Journals
- Frontiers in Oncology (2 papers)Annals of Oncology (2 papers)BMC Clinical Pathology (2 papers)EBioMedicine (2 papers)The Lancet (1 paper)
- Partner nations
- SwedenUnited KingdomGermany
In The Last Decade
David Borg
25 papers receiving 2.9k citations
David Borg's Hit Papers
Peers
Comparison fields: 5 of 78
- Oncology 2k
- Pulmonary and Respiratory Medicine 461
- Cancer Research 143
- Immunology 97
- Surgery 206
Countries citing papers authored by David Borg
This map shows the geographic impact of David Borg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Borg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Borg more than expected).
Fields of papers citing papers by David Borg
This network shows the impact of papers produced by David Borg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Borg. The network helps show where David Borg may publish in the future.
Co-authors
The 25 scholars most cited alongside David Borg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2017 | 1525 |
| 2 | Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial Hit paper breakdown → | 2018 | 411 |
| 3 | 2016 | 315 | |
| 4 | 2019 | 204 | |
| 5 | 2017 | 54 | |
| 6 | 2023 | 53 | |
| 7 | 2016 | 52 | |
| 8 | 2021 | 48 | |
| 9 | 2019 | 37 | |
| 10 | 2023 | 36 | |
| 11 | 2020 | 33 | |
| 12 | 2016 | 27 | |
| 13 | 2016 | 27 | |
| 14 | 2016 | 23 | |
| 15 | 2021 | 23 | |
| 16 | 2015 | 18 | |
| 17 | 2009 | 16 | |
| 18 | 2022 | 15 | |
| 19 | 2024 | 11 | |
| 20 | 2017 | 10 |
About David Borg
David Borg is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 26 papers that have together received 3k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (10 papers), Cancer Immunotherapy and Biomarkers (7 papers), Esophageal Cancer Research and Treatment (6 papers), Pancreatic and Hepatic Oncology Research (4 papers), HER2/EGFR in Cancer Research (4 papers), Immune cells in cancer (2 papers), Cancer Cells and Metastasis (1 paper) and Colorectal Cancer Treatments and Studies (1 paper). The work is most often cited by research in Oncology (2k citations), Pulmonary and Respiratory Medicine (461 citations), Cancer Research (143 citations), Immunology (97 citations) and Surgery (206 citations). David Borg has collaborated with scholars based in Sweden, United Kingdom and Germany. Frequent co-authors include Karin Jirström, Björn Nodin, Charlotta Hedner, Bobby Tingstedt, Daniel Ansari, Caroline Williamsson, Monika Posaric Bauden, Agata Sasor, Christian Sturesson and Roland E. Andersson. Their work appears in journals such as Frontiers in Oncology, Annals of Oncology, BMC Clinical Pathology, EBioMedicine and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.